VIVIAN SONA: Open Payments
NPI 1902358377 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,443 in 129 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $396 · 2025 $2,443
Food & beverage: $2,443
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $308 |
| Janssen Pharmaceuticals, Inc | 19 | $304 |
| ABBVIE INC. | 15 | $275 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $227 |
| E.R. Squibb & Sons, L.L.C. | 11 | $210 |
| Teva Pharmaceuticals USA, Inc. | 9 | $196 |
| Axsome Therapeutics, Inc. | 10 | $187 |
| Lundbeck LLC | 9 | $145 |
| Corium, LLC | 4 | $131 |
| Indivior Inc. | 6 | $123 |
Products named: REXULTI, VRAYLAR, CAPLYTA, COBENFY, Auvelity, INVEGA SUSTENNA, SPRAVATO, Azstarys.
Industry payments across TX — which companies pay providers there.
